Numbers

The Numbers

Tenet Healthcare has spent the last seven years quietly converting from a leveraged, low-margin hospital operator into a deleveraged, ambulatory-led cash machine — operating margin has tripled from roughly 5% in FY2017 to 15% in FY2025, free cash flow has gone from negative-to-flat to $2.5B, and net debt is down by a third. The market has paid for it: the stock is up roughly 6x since 2020. The single number most likely to re-rate or de-rate the shares from here is EV/EBITDA on a clean, post-divestiture EBITDA base: at 6.4x today the shares trade about one turn below the 16-year mean of 8.3x, which is what investors get paid to underwrite continued execution against a slow-growth, regulation-heavy hospital backdrop.

The Quality Score is a 0–100 composite of profitability, balance-sheet health, predictability and cash-conversion strength derived from the financials shown below. Fair Value is the base-case triangulation from EV/EBITDA mean reversion and is detailed in the closing section.

Price as of 2026-05-01. Tenet operates 50 acute-care hospitals plus a controlling interest in USPI, the country's largest network of ambulatory surgery centers (≈518 ASCs as of year-end 2024). After divesting nine hospitals across South Carolina, California and Alabama in 2024, the mix has tilted decisively toward higher-margin ambulatory work.

Quality Scorecard

The scorecard combines fundamentals-based health checks readers care about — distress risk (Altman Z), accounting durability (Piotroski F), capital efficiency (ROIC, ROE), and earnings volatility. Scoring is computed from current filings.

The picture is a mid-quality compounder rather than a fortress: profitability and cash conversion are now genuinely strong, but Altman Z still sits in the grey zone because of intangible-heavy assets and a long history of episodic write-downs. Predictability is the soft spot — earnings have been distorted by impairments (2017), the pandemic (2020–21), and divestiture gains (2024), making clean comparables hard.

Revenue and Earnings Power — 16-Year View

Revenue jumped on the 2013 Vanguard Health acquisition and again on the 2015 USPI roll-up, then plateaued near $18–21B as the company sold underperforming hospitals. The margin story is the more important one: operating margin doubled from the mid-single-digits of 2013–17 to a structural 11–15% range from 2021 onwards, driven by mix shift toward ambulatory, contract renegotiations with payers, and 30+ hospital divestitures. FY2024's 27.6% operating margin is not the new run-rate — it includes a $2.916B pre-tax gain on hospital divestitures; the underlying margin was closer to 13–14%.

Quarterly Direction

Revenue is remarkably steady at $5.0–5.5B per quarter — the divestitures stripped capacity but pricing/mix offset most of it. The operating-margin spike in 1Q24 (60%) is the single $2.9B divestiture gain landing in one quarter. The underlying quarterly margin run-rate is 13–17%, with 1Q26 starting the year at 23% — a strong setup heading into the May earnings print.

Cash Generation — Are the Earnings Real?

Cash conversion is the story behind the rerate. Trailing five-year FCF / Net Income runs 129% ($8.5B FCF on $9.5B net income), with FCF exceeding net income in seven of the last ten years. FY2024 looks like an inversion only because reported NI included a non-cash $2.9B divestiture gain; on a clean basis, OCF still tracks above adjusted NI. Capex has crept higher (now $1.0B vs $0.7B average) reflecting investment in ASC build-outs, but FCF is still hitting record levels.

Capital Allocation

The capital allocation playbook flipped between 2022 and 2025. Acquisitions averaged over $1B / year in 2020–21 (USPI minority buy-in), then collapsed; buybacks took over, scaling from zero to $1.39B in 2025 — the largest in the company's history. Net debt repayment has been a constant $2–3B / year drumbeat, funded partly by re-issuance at lower coupons. There is no dividend.

Balance Sheet Health

Net debt has come down only modestly ($14.5B → $10.3B over 7 years) — the deleveraging story is really about the denominator. EBITDA more than doubled, dropping ND/EBITDA from a balance-sheet-stretched 8x in 2015 to a comfortable 2.5x today. FY2024's 1.6x reading is again the divestiture distortion. This single trajectory explains most of the equity rerate: hospital operators with ND/EBITDA above 5x trade as "stressed credit"; below 3x they trade like consumer-defensives.

Stock Price — The Rerate

The shares went from $14 in March 2020 to over $200 by mid-2025 — a 14-bagger driven almost entirely by EBITDA expansion and multiple normalization, not multiple expansion alone. The pull-back from $203 to $183 over the past two quarters is part profit-taking, part recognition that the divestiture EBITDA tailwind is largely complete.

Valuation — Now vs Its Own 16-Year History

This is the chart that answers the only question that matters for new money: is the rerate done, or is there more to come?

At 6.4x EBITDA, the shares trade roughly one full turn below the 16-year mean but in line with the 5-year average. The market is asking for proof that FY2024's adjusted EBITDA base ($3.6B clean of the divestiture gain) compounds, rather than reverts. If EBITDA stays around $4B and the multiple drifts back to its 16-year norm, the math points to the high-$200s. If the market loses confidence and the multiple falls to the 5.5x trough seen post-2017, the stock has roughly $122 of fundamental support — about 33% downside from here.

Per-Share Economics

Three things stand out: (1) EPS turned reliably positive only in 2020, (2) book value per share crossed zero in the same year after a decade of negative book from aggressive buybacks at low prices, and (3) FCF per share has roughly tripled to $27.85 since 2018 — that's the engine of the rerate. The company has retired 14% of shares since 2022.

Peer Comparison — FY2025

Tenet now leads the peer set on FCF margin (11.9%) — ahead of even HCA (10.2%) — with a cleaner balance sheet (2.5x ND/EBITDA) than stretched HCA (4.5x) or stressed CYH (6.5x). HCA still scores higher on operating margin and absolute scale and trades at a quality premium; CYH is the value trap; EHC is the smaller, higher-multiple compounder. THC sits as the "good-quality, fair-price" mid-cap option. ROE is left blank for HCA and CYH because equity is negative — both have run buybacks far enough to wipe out book equity.

Fair Value Range

What the Numbers Say

The numbers confirm that Tenet has executed a real, durable margin transformation: operating margin tripled, FCF turned consistently positive at over a billion dollars a year, ND/EBITDA went from distressed to investment-grade-adjacent, and per-share book value finally turned positive after a decade underwater. They contradict the headline narrative that 2024 was a structural step-change — a third of FY2024 operating income was a one-shot divestiture gain, and the FY2025 numbers (with operating margin re-normalizing to 15% and EBITDA back near $4.1B) are the real apples-to-apples comparison. Watch in the next four quarters: (1) whether ASC same-store growth at USPI stays in the high single digits, (2) whether the buyback pace ($1.4B in 2025) sustains into 2026 absent further divestitures, and (3) the May 2026 Q1 print — consensus is $4.42 EPS and the company already reported $8.01, so the next step is whether the run-rate margin in Hospital Operations holds above 13%.